<HashMap><database>EGA</database><scores/><additional><omics_type>Genomics</omics_type><dataset_type>N/A</dataset_type><full_dataset_link>https://ega-archive.org/datasets/EGAD00001011312</full_dataset_link><sample_count>204</sample_count><description>EGA dataset EGAD00001011312</description><repository>EGA</repository><title>INSPIRE multi-timepoint cfMeDIP dataset</title></additional><is_claimable>false</is_claimable><name>4ff93368-7c31-4e6a-bf55-214498fab031 - samples</name><description>This dataset contains raw sequencing data from multi-timepoint cell-free methylated DNA immunoprecipitation and sequencing (cfMeDIP-seq) of plasma samples from the INSPIRE study (NCT02644369). Details about the study, including inclusion/exclusion criteria and interventions are available at https://clinicaltrials.gov/study/NCT02644369. Briefly, five cohorts were included, INS-A (head &amp; neck squamous cell carcinoma), INS-B (triple-negative breast cancer), INS-C (high-grade serous ovarian cancer), INS-D (melanoma), and INS-E (mixed solid tumors). All patients in the study were diagnosed with advanced cancer and received treatment with pembrolizumab. Plasma samples were collected at baseline and every 3 cycles until disease progression, death, loss of follow-up, or completion of the study. Plasma samples were first processed for cell-free DNA mutations and remaining samples were then processed by cfMeDIP-seq, prioritizing baseline and post-cycle 3 samples. In total, data from 204 timepoints from 87 distinct patients are deposited.</description><dates><updated>2024-03-26 16:10:03</updated></dates><accession>EGAD00001011312</accession><cross_references><TAXONOMY>9606</TAXONOMY><EGA>EGAC00001000912</EGA><EGA>EGAS00001003280</EGA></cross_references></HashMap>